Clinical trials: Ovarian Endometrioid Tumor
Ovarian Neoplasms
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1 Proto-Oncogene, Serine/Threonine Kinase (RAF1) and…
- Trial name
- NCT02736305
- Testing
- Regorafenib
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore